The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1

被引:114
作者
Antonicka, Hana
Sasarman, Florin
Kennaway, Nancy G.
Shoubridge, Eric A.
机构
[1] McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada
[2] McGill Univ, Dept Human Genet, Montreal, PQ H3A 2B4, Canada
[3] Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA
基金
加拿大健康研究院;
关键词
D O I
10.1093/hmg/ddl106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Defects in mitochondrial translation are associated with a remarkable, but unexplained diversity of clinical phenotypes. Here we have investigated the molecular basis for tissue specificity in patients with a fatal hepatopathy due to mutations in the mitochondrial translation elongation factor EFG1. Blue-native gel electrophoresis revealed unique, tissue-specific patterns in the nature and severity of the defect. Liver was the most severely affected tissue, with less than 10% residual assembly of complexes I and IV, and a 50% decrease in complex V. Skeletal muscle showed a 50% reduction in complex I, and complexes IV and V were 20% of control. In fibroblasts, complexes I and IV were 20% of control, and there was a 40-60% reduction in complexes III and V. In contrast, except for a 50% decrease in complex IV, all complexes were near normal in heart. The severity of the defect paralleled the steady-state level of the mutant EFG1 protein, which varied from 60% of control in heart to undetectable in liver. The ratio of translation elongation factors EFTu:EFTs increased from 1:6 to 1:2 in patient heart, whereas in liver it decreased from 1:1 to 1:4. Over-expression of either EFTu or EFTs in control and patient fibroblasts produced dominant negative effects, indicating that the relative abundance of these factors is an important determinant of translation efficiency. Our results demonstrate marked differences among tissues in the organization of the mitochondrial translation system and its response to dysfunction, and explain the severe hepatopathy, but normal cardiac function in EFG1 patients.
引用
收藏
页码:1835 / 1846
页数:12
相关论文
共 34 条
[1]   SEQUENCE AND ORGANIZATION OF THE HUMAN MITOCHONDRIAL GENOME [J].
ANDERSON, S ;
BANKIER, AT ;
BARRELL, BG ;
DEBRUIJN, MHL ;
COULSON, AR ;
DROUIN, J ;
EPERON, IC ;
NIERLICH, DP ;
ROE, BA ;
SANGER, F ;
SCHREIER, PH ;
SMITH, AJH ;
STADEN, R ;
YOUNG, IG .
NATURE, 1981, 290 (5806) :457-465
[2]  
BOSCH L, 1983, PROG NUCLEIC ACID RE, V30, P91
[3]  
BOULET L, 1992, AM J HUM GENET, V51, P1187
[4]  
Cai YC, 2000, PROTEIN SCI, V9, P1791
[5]   REFERENCE CHARTS FOR RESPIRATORY-CHAIN ACTIVITIES IN HUMAN TISSUES [J].
CHRETIEN, D ;
RUSTIN, P ;
BOURGERON, T ;
ROTIG, A ;
SAUDUBRAY, JM ;
MUNNICH, A .
CLINICA CHIMICA ACTA, 1994, 228 (01) :53-70
[6]   Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency [J].
Coenen, MJH ;
Antonicka, H ;
Ugalde, C ;
Sasarman, F ;
Rossi, R ;
Heister, JGAMA ;
Newbold, RF ;
Trijbels, FJMF ;
van den Heuvel, LP ;
Shoubridge, EA ;
Smeitink, JAM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (20) :2080-2086
[7]   Mechanisms of disease: Mitochondrial respiratory-chain diseases [J].
DiMauro, S ;
Schon, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (26) :2656-2668
[8]   Cloning and characterization of human and mouse mitochondrial elongation factor G, GFM and Gfm, and mapping of GFM to human chromosome 3q25.1-q26.2 [J].
Gao, J ;
Yu, L ;
Zhang, PZ ;
Jiang, JM ;
Chen, J ;
Peng, JS ;
Wei, YH ;
Zhao, SY .
GENOMICS, 2001, 74 (01) :109-114
[9]   Identification and characterization of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution [J].
Hammarsund, M ;
Wilson, W ;
Corcoran, M ;
Merup, M ;
Einhorn, S ;
Grandér, D ;
Sangfelt, O .
HUMAN GENETICS, 2001, 109 (05) :542-550
[10]   Disorders of mitochondrial protein synthesis [J].
Jacobs, HT .
HUMAN MOLECULAR GENETICS, 2003, 12 :R293-R301